Browsing by Author "Dawoud, Marwa H.S"

Now showing 1 - 3 of 3

Chewing gum containing repaglinide solid dispersion using mesoporous silica nanoparticles for management of diabetes mellitus: In-vitro evaluation and clinical appraisal
(Editions de Sante, 2024-02) Badawi, Noha M; Amer, Reham I; Attia, Dalia A; Fayez, Ahmed M; Dawoud, Marwa H.S
The current study aimed to formulate repaglinide solid dispersion via mesoporous silica nanoparticles (R-MSNs) as a carrier in an attempt to enhance drug solubility. Then incorporation of it in a medicated chewing gum (MCG); to enhance the drug bioavailability, for the treatment of diabetes mellitus. R-MSNs solid dispersion formulations (R-MSNs-SD) were prepared using the solvent evaporation method. The chosen formula was investigated in terms of FTIR, DSC, and XRD in addition to morphology that was studied by SEM. The results demonstrated that repaglinide was successfully loaded into the pores of MSNs. The cytotoxicity of the chosen formula was evaluated by SRB assay using a Vero cell line and the cytotoxic effect of repaglinide was found to be diminished when incorporated within MSNs. Subsequently, MCGs were formulated using the chosen R-MSNs-SD as well as pure repaglinide and tested for physical properties, content uniformity, and drug release. The results exhibited a notable improvement in the release of repaglinide from the MCG containing pure repaglinide and RMSNs-SD. A clinical investigation was further conducted on diabetic patients for MCGs containing R-MSNs-SD or pure repaglinide and compared to the marketed product where the blood glucose level was measured. MCG formulations specially the one loaded with R-MSNs-SD showed enhanced antidiabetic activity than the marketed product suggesting a promising oral antidiabetic delivery system for repaglinide.
Optimization of nanovesicular carriers of a poorly soluble drug using factorial design methodology and artificial neural network by applying quality by design approach
(Taylor and Francis Ltd., 09/12/2021) Dawoud, Marwa H.S; Fayez, Ahmed M; Mohamed, Reem A; Sweed, Nabila M
The aim of the current work is to utilize quality by design (QbD) approach to develop and optimize nanovesicular carriers of a hydrophobic drug. Rosuvastatin calcium was used as a model drug, which suffers poor bioavailability. Several tools were used in the risk assessment study as Ishikawa diagrams. The critical process parameters (CPP) were found to be the particle size, polydispersity index, zeta potential and entrapment efficiency. Factorial design was used in risk analysis, which was complemented with artificial neural network (ANN); to assure its accuracy. A design space was established, with an optimized nanostructured lipid carrier formula containing 3.2% total lipid content, 0.139% surfactant and 0.1197 mg % drug. The optimized formula showed a sustained drug release up to 72 hours. It successfully lowered each of the total cholesterol, low density lipoprotein and triglycerides and elevated the high-density lipoprotein levels, as compared to the standard drug. Thus, the concurrent use of the factorial design with ANN using QbD approach permitted the exploration of the experimental regions for a successful nanovesicular carrier formulation, and could be used as a reference for many nanostructured drug delivery studies during their pharmaceutical development and product manufacturing.
The pulmonary protective potential of vanillic acid-loaded TPGS-liposomes: modulation of miR-217/MAPK/NF-κb signalling pathway
(Taylor and Francis Ltd, 2024-04) Sweed, Nabila M; Zaafan, Mai A; El-Bishbishy, Mahitab H; Dawoud, Marwa H.S
The aim is to investigate the possible pulmonary protective effect of vanillic acid (VA) in liposome-TPGS nanoparticles, to overcome VA’s poor bioavailability. VA was successfully extracted. Liposomes were prepared using thin film hydration. Central composite design was adopted for optimisation of liposomes to get the maximum entrapment efficiency (EE%) and the minimum mean diameter, where the liposomes were further modified with TPGS, and tested for PDI, zeta-potential, and in-vitro drug release. In-vivo study on mice with LPS-acute pulmonary toxicity was tested. TPGS-modified VA-liposomes showed EE% of 69.35 ± 1.23%, PS of 201.7 ± 3.23 nm, PDI of 0.19 ± 0.02, and zeta-potential of −32.2 ± 0.32 mv. A sustained drug release of the TPGS-modified VA-liposomes was observed compared to standard VA, and a pulmonary-protective effect through decreasing miR-217 expression with subsequent anti-inflammatory effect through suppression of MAPK and PI3K/NF-κB pathways was also demonstrated in the current study. TPGS-modified VA-liposomes showed an enhanced bioavailability and a sustained drug release with promising pulmonary protective effects against acute pulmonary injury diseases.